Heart insufficiency after combination of verapamil and metoprolol: A fatal case report and literature review

The combination of verapamil or diltiazem with beta‐blockers should be avoided because of potentially profound adverse effects on AV (atrioventricular) nodal conduction, heart rate, or cardiac contractility. This effect is unpredictable but may be enhanced due to CYP2D6 poor metabolizer status which...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical case reports 2019-11, Vol.7 (11), p.2042-2048
Hauptverfasser:	Saedder, Eva A., Thomsen, Asser Hedegård, Hasselstrøm, Jørgen Bo, Jornil, Jakob Ross
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood pressure Cancer Cardiac arrhythmia cardiac insufficiency cardiovascular toxicology Case Report Case Reports CYP2D6 Cytochrome Drug dosages drug‐drug interaction Fungal infections Genotype & phenotype Heart failure Heart rate Hospitalization Hospitals Hypertension Metabolism Metabolites metoprolol Patients verapamil
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The combination of verapamil or diltiazem with beta‐blockers should be avoided because of potentially profound adverse effects on AV (atrioventricular) nodal conduction, heart rate, or cardiac contractility. This effect is unpredictable but may be enhanced due to CYP2D6 poor metabolizer status which could be a special vulnerability factor. The combination of verapamil or diltiazem with beta‐blockers should be avoided because of potentially profound adverse effects on AV nodal conduction, heart rate, or cardiac contractility. This effect is unpredictable but may be enhanced due to CYP2D6 poor metabolizer status which could be a special vulnerability factor.
ISSN:	2050-0904 2050-0904
DOI:	10.1002/ccr3.2393